STUDY GOAL: To compare the efficacy and safety of single 1 g oral azithromycin with doxycycline, 100 mg twice daily for seven days for treatment of uncomplicated urogenital chlamydial infection. STUDY DESIGN: Randomised, unblinded, comparative trial, involving 597 patients demonstrating clinical evidence of genital chlamydia and a positive non-culture assay for Chlamydia trachomatis. RESULTS: Among the azithromycin- and doxycycline-treated patients 61% and 60%, respectively, were asymptomatic within one week after the first dose. At two weeks, these figures increased to 86% and 83%, respectively. Bacteriological eradication, based on a negative assay, occurred in 338 (97%) of 347 azithromycin-treated patients and 161 (99%) of 163 doxycycline-treated patients. CONCLUSION: Treatment of uncomplicated chlamydial cervicitis and urethritis with single 1 g oral azithromycin is equivalent to standard therapy with doxycycline. Drug-related adverse events were approximately twice as common as previously reported for both drugs.
RCT Entities:
STUDY GOAL: To compare the efficacy and safety of single 1 g oral azithromycin with doxycycline, 100 mg twice daily for seven days for treatment of uncomplicated urogenital chlamydial infection. STUDY DESIGN: Randomised, unblinded, comparative trial, involving 597 patients demonstrating clinical evidence of genital chlamydia and a positive non-culture assay for Chlamydia trachomatis. RESULTS: Among the azithromycin- and doxycycline-treated patients 61% and 60%, respectively, were asymptomatic within one week after the first dose. At two weeks, these figures increased to 86% and 83%, respectively. Bacteriological eradication, based on a negative assay, occurred in 338 (97%) of 347 azithromycin-treated patients and 161 (99%) of 163 doxycycline-treated patients. CONCLUSION: Treatment of uncomplicated chlamydial cervicitis and urethritis with single 1 g oral azithromycin is equivalent to standard therapy with doxycycline. Drug-related adverse events were approximately twice as common as previously reported for both drugs.
Authors: O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton Journal: J Antimicrob Chemother Date: 1990-01 Impact factor: 5.790
Authors: Christine M Khosropour; Teal R Bell; James P Hughes; Lisa E Manhart; Matthew R Golden Journal: Sex Transm Dis Date: 2018-05 Impact factor: 2.830
Authors: Carol Páez-Canro; Juan Pablo Alzate; Lina M González; Jorge Andres Rubio-Romero; Anne Lethaby; Hernando G Gaitán Journal: Cochrane Database Syst Rev Date: 2019-01-25
Authors: Fengchen Liu; Travis C Porco; Harran A Mkocha; Beatriz Muñoz; Kathryn J Ray; Robin L Bailey; Thomas M Lietman; Sheila K West Journal: Epidemics Date: 2014-01-08 Impact factor: 4.396
Authors: Annette Prohl; Markus Lohr; Carola Ostermann; Elisabeth Liebler-Tenorio; Angela Berndt; Wieland Schroedl; Michael Rothe; Evelyn Schubert; Konrad Sachse; Petra Reinhold Journal: PLoS One Date: 2015-03-13 Impact factor: 3.240